Stenotrophomonas maltophilia as a causative agent of implant-associated infection in trauma and orthopedic patients
https://doi.org/10.34215/1609-1175-2024-1-43-47
Abstract
Objective. To evaluate an etiologic significance of S. maltophilia in the development of orthopedic implant-associated infections. Materials and methods. The study involved a retrospective analysis of the frequency of excretion of S. maltophilia in patients with periprosthetic infection and osteomyelitis, using the Microbe-2 program in period of 2005–2020. Clinical isolates were excreted according to standard methods. Identification was performed via Microlatest panels using iEMS Reader MF. Antibiotic susceptibility was studied in accordance with EUCAST. Results. Over 16 years 69 strains of S. maltophilia have been identified, comprising 0.33% of all isolated pathogens (n=20631). 50% of isolates were excreted from tissue biopsies, 30% – from wound exudates. In 89% of cases, S. maltophilia was isolated in microbial associations, including 65% of cases together with Grampositive bacteria, 18% with other non-fermenting Gram-negative bacteria, and 6% with other pathogens. 63% appeared sensitive to trimethoprim/sulfamethoxazole and 25.5% of isolates were resistant. The proportion of cultures sensitive to this drug was found to increase from 63% in 2011–2014 to 81% in 2015–2019 (p = 0.08). Conclusion. S. maltophilia should be considered as a causative etiologic agent of severe chronic orthopedic infections.
About the Authors
E. M. Gordina
Vreden National Medical Research Center of Traumatology and Orthopedics
Russian Federation
Russian Federation
Ekaterina M. Gordina, Cand. Sci. (Med.), senior researcher of the division of wound infection treatment and prevention
8, Akademika Baykova street, St. Petersburg, 195427
S. A. Bozhkova
Vreden National Medical Research Center of Traumatology and Orthopedics
Russian Federation
Russian Federation
St. Petersburg
A. N. Rukina
Vreden National Medical Research Center of Traumatology and Orthopedics
Russian Federation
Russian Federation
St. Petersburg
References
1. Mojica MF, Humphries R, Lipuma JJ, Mathers AJ, Rao GG, Shelburne SA, Fouts DE, Van Duin D, Bonomo RA. Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob Resist. 2022; 4(3):dlac040. doi: 10.1093/jacamr/dlac040
2. Hashimoto T, Komiya K, Fujita N, Usagawa Y, Yamasue M, Umeki K, Ando M, Nureki SI, Hiramatsu K, Kadota JI. Risk factors for 30-day mortality among patients with Stenotrophomonas maltophilia bacteraemia. Infect Dis (Lond). 2020; 52(6):440–2. doi: 10.1080/23744235.2020.1734653
3. Kim EJ, Kim YC, Ahn JY, Jeong SJ, Ku NS, Choi JY, Yeom JS, Song YG. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impactof quinolone-resistant strains. BMC Infect Dis. 2019; 19(1):754. doi: 10.1186/s12879-019-4394-4
4. Imoto W, Yamada K, Yamairi K, Shibata W, Namikawa H, Yukawa S, Yoshii N, Nakaie K, Hirose A, Koh H, Watanabe T, Asai K, Nakamae H, Kaneko Y, Kawaguchi T, Hino M, Kakeya H. Clinical characteristics of rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia. Intern Med. 2020; 59:193–8. doi: 10.2169/internalmedicine.3358-19
5. Chesnutis EJ 3rd, Ng A, Kruse D, Stone PA. Stenotrophomonas maltophilia: A Rare Case of Osteomyelitis After an Open Distal Tibial Fracture. J Foot Ankle Surg. 2018; 57(5):1037–41. doi: 10.1053/j.jfas.2018.03.001
6. Brooke JS. Advances in the Microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev. 2021; 34(3):e0003019. doi: 10.1128/CMR.00030-19
7. Mercier-Darty M, Royer G, Lamy B, Charron C, Lemenand O, Gomart C, Fourreau F, Madec JY, Jumas-Bilak E, Decousser JW. Comparative Whole-Genome Phylogeny of Animal, Environmental, and Human Strains Confirms the Genogroup Organization and Diversity of the Stenotrophomonas maltophilia Complex. Appl Environ Microbiol. 2020; 86(10):e02919–19. doi: 10.1128/AEM.02919-19
8. Geller M, Nunes CP, Oliveira L, Nigri R. S. maltophilia pneumonia: A case report. Respir Med Case Rep. 2018;24:44–5. doi: 10.1016/j.rmcr.2018.04.004
9. Winkler T, Trampuz A, Renz N, Perka С, Bozhkova SА. Classification and algorithm for diagnosis and treatment of hip prosthetic infection. Traumatology and orthopedics of Russia. 2016(1):33–45 (In Russ.).
10. Wang G, Xu N, Yang L, Zheng F, Sai L, Zhou J, Yang S. Community acquired Stenotrophomonas maltophilia discitis: Diagnosis aided by shotgun metagenomic sequencing. Int J Infect Dis. 2019; 81:1–3. doi: 10.1016/j.ijid.2019.01.032
11. Hantes ME, Papageorgiou F, Komnos GA. Stenotrophomonas maltophilia periprosthetic joint infection after reverse total shoulder arthroplasty. IDCases. 2020;21:e00796. doi: 10.1016/j.idcr.2020.e00796
12. Hamdi AM, Fida M, Abu Saleh OM, Beam E. Stenot rophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience. Open Forum Infect Dis. 2020;7(1):ofaa008. doi: 10.1093/ofid/ofaa008
13. Sarzynski SH, Warner S, Sun J, Matsouaka R, Dekker JP, Babiker A, Li W, Lai YL, Danner RL, Fowler VG. Jr, Kadri SS. Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals. Open Forum Infect Dis. 2022; 9(2):ofab644. doi: 10.1093/ofid/ofab644
14. Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS. Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the sentry Antimicrobial Surveillance Program (1997–2016). Open Forum Infect Dis. 2019;6(Suppl 1):S34–S46. doi: 10.1093/ofid/ofy293
15. Flores-Treviño S, Bocanegra-Ibarias P, Camacho-Ortiz A, Morfín-Otero R, Salazar-Sesatty HA, Garza-González E. Stenotrophomonas maltophilia biofi lm: its role in infectious diseases. Expert Rev Anti Infect Ther. 2019;17(11):877–93. doi: 10.1080/14787210.2019.1685875
16. Hu LF, Chen GS, Kong QX, Gao LP, Chen X, Ye Y, Li JB. Increase in the Prevalence of Resistance Determinants to Trimethoprim/ Sulfamethoxazole in Clinical Stenotrophomonas maltophilia Isolates in China. PLoS One. 2016;11(6):e0157693. doi: 10.1371/journal.pone.0157693
Review
For citations:
Gordina E.M., Bozhkova S.A., Rukina A.N. Stenotrophomonas maltophilia as a causative agent of implant-associated infection in trauma and orthopedic patients. Pacific Medical Journal. 2024;(1):43-47. (In Russ.) https://doi.org/10.34215/1609-1175-2024-1-43-47
Views:
1379
Email this article 